间充质干细胞肿瘤基因治疗现状
首发时间:2012-11-16
摘要:间充质干细胞(MSCs)因其作为细胞载体用于基因治疗具有长期性和靶向性已成为治疗恶性肿瘤的研究热点。应用病毒载体将目的基因导入MSCs具有高效性。MSCs可以携载免疫抑制基因、自杀基因和血管抑制基因发挥其细胞载体作用。但是,MSCs在用于肿瘤治疗时表现在不同研究小组及/或不同肿瘤截然相反的作用给MSCs应用的安全性带来极大的隐患。MSCs具有可朔性,它可分化为内皮细胞参与血管生成。MSCs能释放促血管生成因子和抗凋亡分子促进肿瘤血管生成。这两种特性无疑会消减甚至逆转MSCs作为基因载体时发挥抗肿瘤基因治疗的效果,甚至给肿瘤基因治疗带来极大的安全隐患。因此, MSCs作为基因载体安全有效的用于抗肿瘤基因治疗是目前函待解决的问题。
For information in English, please click here
The current situation of tumor gene therapy mediated by mesenchymal stem cells
Abstract:Mesenchymal stem cells (MSCs), as cellular vectors, have become research hotspot in malignant tumor gene therapy for its long-term and tropism.Viral vectors are used in MSCs-based gene therapy with high efficiency. MSCs can carry immune suppressor gene, suicide gene and vascular suppress genes when they used as cell carrier. However, MSCs show opposite effects when present in different research groups and / or different tumors, which bring great risks for MSCs used in tumor gene therapy. MSCs have plasticity, which can participate in angiogenesis by differentiating into endothelial cells. MSCs also promote tumor angiogenesis for their releasing angiogenic factors and anti-apoptotic molecules. The two features will reduce and even reverse treatment effectiveness of MSCs, even bring huge safety trouble in antitumor gene therapy. Therefore, it is an issue to be resolved for MSCs that they are used in anti-tumor gene therapy with safety and effectivity.
Keywords: Tumor gene therapy Mesenchymal stem cells Cell carrier Security
基金:
论文图表:
引用
No.****
同行评议
共计0人参与
勘误表
间充质干细胞肿瘤基因治疗现状
评论
全部评论0/1000